IP Library › Granted Patent US 12697386
Granted Patent B2
US 12697386 · App. 16/966,503 · Granted Aug 4, 2026

Nucleic acid antibody constructs for use against Ebola virus

Inventor: David Weiner (Merion, PA)
Assignee: The Wistar Institute of Anatomy and Biology
A61K39/42A61K48/005A61P31/14C07K16/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12697386
App. No.
16/966,503
Granted
Aug 4, 2026
Kind
B2
Abstract

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an Ebola viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an Ebola virus infection in a subject using said composition and method of generation.

Claims (30)

1 . A composition comprising a first, a second, a third, a fourth, a fifth, and a sixth nucleotide sequence,

wherein the first nucleotide sequence encodes SEQ ID NO: 1;

wherein the second nucleotide sequence encodes SEQ ID NO: 3;

wherein the third nucleotide sequence encodes SEQ ID NO: 5;

wherein the fourth nucleotide sequence encodes SEQ ID NO: 7;

wherein the fifth nucleotide sequence encodes SEQ ID NO: 9; and

wherein the sixth nucleotide sequence encodes SEQ ID NO: 11.

2 . The composition of claim 1 , wherein the composition further comprises at least one nucleotide sequence encoding a protease cleavage site.

3 . The composition of claim 1 ,

wherein the first nucleotide sequence comprises a nucleotide sequence having at least 99% identity to SEQ ID NO:2;

wherein the second nucleotide sequence comprises a nucleotide sequence having at least 99% identity to SEQ ID NO:4;

wherein the third nucleotide sequence comprises a nucleotide sequence having at least 99% identity to SEQ ID NO:6;

wherein the fourth nucleotide sequence comprises a nucleotide sequence having at least 99% identity to SEQ ID NO:8;

wherein the fifth nucleotide sequence comprises a nucleotide sequence having at least 99% identity to SEQ ID NO:10; and

wherein the sixth nucleotide sequence comprises a nucleotide sequence having at least 99% identity to SEQ ID NO:12.

4 . The composition of claim 3 ,

wherein the first nucleotide sequence comprises SEQ ID NO:2;

wherein the second nucleotide sequence comprises SEQ ID NO:4;

wherein the third nucleotide sequence comprises SEQ ID NO:6;

wherein the fourth nucleotide sequence comprises SEQ ID NO:8;

wherein the fifth nucleotide sequence comprises SEQ ID NO: 10; and

wherein the sixth nucleotide sequence comprises SEQ ID NO:12.

5 . The composition of claim 1 , wherein at least one of the nucleotide sequences further encodes a leader sequence linked at the N terminus of the amino acid sequence.

6 . The composition of claim 1 , wherein the composition comprises at least one expression vector.

7 . The composition of claim 1 , further comprising a pharmaceutically acceptable excipient.

8 . The composition of claim 1 , wherein the first nucleotide sequence and the second nucleotide sequence encode an amino acid sequence having at least 99% identity to SEQ ID NO:13.

9 . A method of treating an Ebola virus infection in a subject, the method comprising administering to the subject the composition of claim 1 .

10 . A method of inducing an immune response against an Ebola virus infection in a subject, the method comprising administering to the subject the composition of claim 1 .

11 . A method of treating an Ebola virus infection in a subject, the method comprising administering to the subject the composition of claim 7 .

12 . A method of inducing an immune response against an Ebola virus infection in a subject, the method comprising administering to the subject the composition of claim 7 .